The angiogenesis inhibitor cediranib demonstrated acceptable activity and a tolerable safety profile as a monotherapy for patients with recurrent or persistent endometrial cancer.
Darcy Lewis
Articles by Darcy Lewis
The addition fosbretabulin tromethamine to bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in pretreated patients with recurrent ovarian cancer enrolled in the phase II GOG186i study.
Circulating tumor cells have previously been reported to be prognostic in other solid tumors: can they become a prognostic biomarker in cervical cancer?
A triage algorithm may identify patients with presumed advanced ovarian cancer who represent preoperatively defined candidates for diagnostic laparoscopy.
Two newly reported studies are providing more insight into the efficacy and safety profile of the PARP inhibitor olaparib in ovarian cancer.
The addition of bevacizumab to a doublet chemotherapy regimen extended OS by nearly 5 months compared with standard chemotherapy alone in women with platinum-sensitive recurrent ovarian cancers.
A 2:1 open-label phase II trial of the FANG vaccine achieved a marked delay in time to progression, in all 14 of 21 patients with stage III/IV ovarian cancer who participated. The other 7 patients did not receive the vaccine.